WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from a pre-specified interim analysis of the Phase III TULIP-SC trial in patients with systemic lupus erythematosus (SLE) showed that the ...

Roche Pharma India launches subcutaneous immunotherapy for lung cancer, Tecentriq SC: Our Bureau, Bengaluru Thursday, May 14, 2026, 17:30 Hrs [IST] Roche Pharma India announced th ...

Subcutaneous mosunetuzumab shows promising efficacy and safety in high-tumor burden follicular lymphoma, paving the way for outpatient treatment options. Safety results shared at ASCO 2025 were ...

SAN DIEGO, Aug. 29, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (HALO) ("Halozyme") today announced the approval of Roche's Tecentriq ® SC (atezolizumab), using Halozyme's ENHANZE ® drug delivery ...

BEERSE, Belgium--(BUSINESS WIRE)--The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the European Commission (EC) has granted marketing authorisation for the expanded use of ...

Roche was granted a Phase 3 clinical trial waiver by CDSCO last year for the Indian launch of Tecentriq SC. The Swiss pharma ...

Targeted Oncology ™ originally published this article. This version has been lightly edited. Subcutaneous (SC) trastuzumab induced stromal tumor infiltrating lymphocyte (sTIL) enrichment and favorably ...

A major amendment has prompted the FDA to extend its review of subcutaneous lecanemab as a starting dose for early Alzheimer disease.

Roche introduces Tecentriq SC, a subcutaneous lung cancer treatment in India, reducing hospital time. Faster, convenient ...

A new post-hoc analysis from the LIBERTY studies, presented at ECCO 2026, demonstrated that initiating subcutaneous (SC) infliximab (Remsima™ SC) after a treatment interruption following intravenous ...

Celltrion, Inc. today announced new data from a post-hoc analysis of the pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC), showing that subcutaneous (SC) infliximab restored and maintained response ...